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ABSTRACT
Background: Pediatric inpatients in United States healthcare settings may be particularly
vulnerable with respect to methicillin-resistant Staphylococcus aureus (MRSA) infection
and transmission. Although infection prevention and control protocols have well been
established for MRSA and for adult inpatients, there are few current guidelines available
on how to address MRSA prevention and control in pediatric inpatients.
Objectives: To systematically identify, describe, and evaluate the quality of the current
literature on infection prevention and control strategies for preventing the transmission of
methicillin-resistant Staphylococcus aureus (MRSA) in United States pediatric inpatient
settings.
Search methods: In June-August 2015, Campbell Collaboration Library, Cochrane
Library, PubMed, MEDLINE, Biological Abstracts, CINAHL Plus, and Web of Science
was searched for studies published between January of 2005 and December 2015 by
using relevant key terms for pediatric patients (ex, children, infant, newborn, neonate)
and prevention and control of MRSA.
Selection criteria: All primary data studies on infection prevention and control
interventions for healthcare associated MRSA in United States pediatric inpatient settings
were eligible for inclusion.
Data collection and analysis: Two authors independently reviewed the results of the
searches. Another author was consulted for any discrepancies between categorization of
articles. Data extraction was conducted by one author and was checked by a second
author.
Main results: 1,619 studies were initially identified, of which 21 studies met the criteria
for inclusion. Of the studies that met inclusion criteria, one was a randomized control
trial, thirteen were retrospective cohort studies, four were before and after studies, two
were prospective cohort studies and one was a retrospective case finding. Three studies
(Song (2010), Robicsek (2009), and Gregory (2009)) found that Mupirocin or antibiotic
treatment did not eradicate MRSA colonization consistently and were unsuccessful in
eliminating continuing transmission of MRSA. However, the study by Delaney found
that there was a significant reduction in rates of S. aureus infection when comparing
Mupirocin prophylactic period with the control period. Another two studies (Constantini
and Kjonegaard) found that screening was not identifying all of the MRSA cases, and
that HA-MRSA infection rates did not decline after implementation of ICU screening,
thus proving that this method was ineffective in regards to decreasing transmission and
incidence of MRSA infections.
Conclusion: There is a lack of research evaluating the effects on MRSA transmission of
infection prevention and control strategies in pediatric inpatient settings. More resources
should be devoted to understand the epidemiology of MRSA amongst the pediatric
inpatient population as well as continued research interventions to establish prevention
and control protocols for this vulnerable population.
KEYWORDS Prevention, Control, MRSA, Neonates, Infant, Pediatrics, Children,
Newborns, NICU, PICU
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CHAPTER I. INTRODUCTION
According to the Department of Health and Human Services, about 1 in every 25
inpatients has an infection associated with hospital care, costing billions of dollars and
about ten thousand lives annually (DHHS, 2015). It is therefore imperative that we treat
hospital-acquired infections in order to reduce excessive expenditures and improve
patient outcomes. One of the most common hospital acquired infections is methicillinresistant Staphylococcus aureus (MRSA). MRSA is an opportunistic gram-positive
bacteria that has in recent years become a serious healthcare as well as community threat.
Staphylococcus aureus asymptomatically colonizes the skin and anterior nares
(nostrils) of approximately one-third of the human population at any given time and two
out of 100 people are carriers for MRSA (CDC, 2013). Consequently, outbreaks of S.
aureus and MRSA are extremely common as many in the population do not know that
they are carriers of the bacteria (Williams, et al., 2010; CDC, 2013). Unfortunately in
today’s society, Staphylococcus aureus has become resistant to common medications
prescribed to treat staph infections. In order to fully understand how MRSA became
resistant to several broad-spectrum antibiotics, it is important to understand the history
that transformed this bacteria.
Although Staphylococcus aureus itself has been around for billions of years, it
was the overuse of Alexzander Flemmings’ development of penicillin in 1928 that caused
the bacteria to become resistant to antibiotics due to acquisitions of genes producing blactamase (Moellering, 2012). In 1959, Methicillin was introduced as a new antibiotic
and within a two-year span, methicillin-resistant Staphylococcus aureus developed. It is

	
  

	
  

also important to note that according to Mayhall (2012), although MRSA got its name
from being methicillin-resistant, MRSA is now not only resistant to anti-staphylococcal
penicillins such as nalcillin and oxacillin but is also resistant to beta-lactam antibiotics
from first through fourth generations of cephalosporins and carbapenems. Since 1961,
MRSA has spread throughout the world, causing many healthcare, community, and
livestock associated infections. According to the CDC (2013), community acquired
MRSA infections are most associated with skin infections, but healthcare associated
infections are associated with life-threatening bloodstream infections (or MRSA
bacteremia), pneumonia, and surgical site infections. For the purpose of this systematic
review, we will be focusing solely on hospital and healthcare associated infections,
however it is important to note the growing prevalence of community and livestock
associated infections.
Nosocomial infections (hospital acquired/healthcare associated) are those that
were not present in the patient prior to hospitalization and occur usually 48-72 hours after
admittance or within 10 days of discharge from the hospital (Jacobs, 2014). Healthcare
associated infections (HAIs) are important to understand because they can cause lifethreatening illnesses that often can be prevented if proper protocol is followed.
MRSA is a nosocomial infection that is associated with high morbidity and
mortality rates. According to Boucher et al; (2008), in 2005 MRSA infections killed an
estimated 19,000 hospitalized Americans, which is higher than combined AIDS,
Tuberculosis, Viral hepatitis, SARS, and Avian influenza deaths in the United States.
When looking at medical device related deaths, another study by Hanberger et al; (2011)
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analyzed 1265 ICUs from 75 countries and found that in ICU patients, MRSA infections
were independently associated with nearly 50% more hospital deaths when compared to
MSSA infections of ICU patients. MRSA has been a common cause of Central Lineassociated Bloodstream Infection (CLABSI), hospital-acquired pneumonia, Catheterassociated Urinary Tract Infections (CAUITs), wound infections, and Surgical Site
Infections (SSIs) (Mayhall, 2012). According to Mayhall (2012), blood stream infections
caused by MRSA have mortality rates that range from 20% to more than 35%. MRSA
has also been associated with longer lengths of stay, as well as increased health costs
(Mayhall, 2012). Corriere & Deckner (2008) and Noskin and colleagues (2005) have
shown that the length of stay for inpatients with S. aureus infection is three times longer
than that of other patients. They also discuss that when looking at MRSA vs. Methicillinsensitive Staphylococcus aureus (MSSA), the average length of stay for MRSA
infections was 20.1 days longer when compared to MSSA infections, resulting in a 55%
longer length of stay.
MRSA affects mostly those with compromised immune systems, those who have
previously taken antibiotics, the elderly, and those with underlying diseases (CDC, 2013).
Because MRSA affects mostly those with compromised immune systems, there is a
higher risk associated with inpatients in the ICU, among those who recently had surgery
or in those who have invasive medical devices such as catheters or intravenous lines.
According to the CDC (2013), the primary mode of transmission for hospitalacquired MRSA is through person-to-person contact, primarily through healthcare worker
contact with patients or, less frequently, through patient to patient contact. Contaminated
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surfaces and medical equipment are the second most common mode of transmission of
MRSA. Due to the fact that MRSA is an opportunistic bacteria that most often impacts
individuals with impaired immune systems, it is extremely important that prevention and
control methods are standardized throughout inpatient settings in order to reduce the risk
of spreading.
In addition to the risk factors discussed above, Mayhall (2012) discusses certain
healthcare delivery risk factors that have been associated with an increased risk of MRSA
infection in inpatient care. Mayhall (2012) found that risk of MRSA increases as the
prevalence of MRSA among hospital patients increases, that risk increases among
persons admitted to a hospital room in which prior room occupant was colonized or
infected with MRSA, and that healthcare worker hand hygiene practices influence risk
for the patient. Lastly, increased MRSA risks have been associated with staffing deficits
and patient overcrowding, thus providing evidence that contact precautions and
environmental cleaning are paramount to preventing hospital acquired infections
(Mayhall, 2012).
Mayhall (2012) also discussed that MRSA was the cause of 56.8% of S. aureus
healthcare-associated pneumonia, 48.6% of S. aureus hospital-acquired pneumonia, and
34.4% of S. aureus Ventilator-associated Pneumonia (VAP), although associating
mortality to those who acquired S. aureus VAP is debatable amongst researchers. The
National Healthcare Safety Network (NHSN) reported 2,045 S. aureus SSI cases from
2006-2007, resulting in 49% of those S. aureus SSI cases were due to MRSA (Calfee,
2014). Not only is MRSA highly associated with the cause of theses infections, but delay
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in recognizing and treating MRSA can have severe consequences such as higher
mortality rates (Corrier & Deckner, 2008).
Because healthcare-associated MRSA is associated with high morbidity and
mortality, MRSA is also associated with high costs of care. Jacobs (2014) found that in
the United States, HAIs infect 1.7 million patients annually, account for 99,000 deaths,
and cost approximately $35.7 to $45 billion. In order to assess how much cost was
attributed per patient, a cohort study was conducted at the U.S. Department of Veterans
Affairs system between 2007-2010 that analyzed inpatient as well as pharmacy costs
during a year following the discharged MRSA patient (Nelson et al., (2015).

Nelson et

al., (2015) found that 3,599 of the 369,743 inpatients had positive MRSA cultures. After
matching positive MRSA cultured patients to controls, patients were followed for a year
and the study found that those MRSA patients had an increased post-discharge pharmacy
cost average of $776 and an increased inpatient cost average of $12,167 (Nelson et al.,
2015). The study also found that MRSA patients were at an increased risk for
readmission, had more prescriptions, and more inpatient days. This study provides
evidence that the cost associated with MRSA patients is substantially higher than that of
inpatients without MRSA. Thus, it is important to implement stricter prevention and
control policies as to not only improve patient health but as to reduce extraneous
spending on a national level.
According to the Active Bacterial Core Surveillance Report in 2012, the total
estimated cases of MRSA infection in the United States was 75,309 with an incidence
rate of 23.99 (CDC, 2012). The national metric for Healthy People 2020 and Department
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of Health and Human Services Action Plan to Prevent Healthcare-Associated Infection
shows that there have been 23,000 fewer cases in the United States in 2012 when
compared to the baseline of 2007-2008, depicting a -30.80% change in healthcare
associated infections (CDC, 2012). Another study by the National Healthcare Safety
Network (NHSN) found that rates of MRSA bloodstream infections occurring in
hospitalized patients fell almost 50% from 1997-2007 (CDC, 2013). A study published
by the Journal of American Medical Association Internal Medicine showed that invasive
MRSA hospital acquired infections declined by 54% from 2005 to 2011 as well as 9,000
fewer deaths in 2011 (CDC, 2013). The decreasing rate of infections provides evidence
that there are fewer morbidities and mortalities from MRSA infections.
However, the University of Chicago Medicine (UCM) and the University
Healthcare Consortium (UHC) published data in 2012 that estimated that the rates of
MRSA in U.S. academic medical centers from 2003-2008 had actually doubled (David,
et al., 2012). Jacobs (2014) discusses that this difference between the UCM and UHC
study and the CDC data could possibly be due to the fact that the CDC only looks at
invasive infections, which excludes skin infections that were included in the UCM and
UHC study. Another study conducted by Jarvis et al., (2012) surveyed all U.S.
Association for Professionals in Infection Control and Epidemiology, members in order
to assess the prevalence of MRSA from August 1 to December 30, 2010 for all inpatients.
The study found that the overall MRSA prevalence rate was 66.4 per 1,000 inpatients,
which was higher than rate reported in their 2006 study, which used the same
methodology. Thus, it appears that there is a decrease in MRSA invasive infections but
an increase in the overall prevalence of MRSA in inpatients.
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Although there is an improvement due to the decrease in the severity of and risk
of mortality as a result of infections, healthcare associated MRSA infections were not
significantly reduced among pediatric populations from 2005-2010, indicating that there
needs to be further research as to why there is an overall improvement among adults but
not for pediatric inpatients (Iwamoto et al., 2013). It is important to study pediatric
populations because according to Milstone et al., (2011) 8.5% of pediatric patients that
were colonized with MRSA on admission developed a MRSA infection. Even more
staggering is the fact that 47% of patients who became colonized with MRSA in the
pediatric ICU developed MRSA infections (Milstone et al., 2011). In comparison,
Hudson et al., (2012) found that the rates of MRSA carriage to be 6-12% in general
hospital patients and 9-24% in ICUs. MRSA is a common bacterial infection amongst
children, especially in the NICU due to their susceptibility to infections. Various
strategies for prevention and eradication have been used with various rates of success, but
implementation of standardized prevention methods needs to be developed specifically
for pediatrics.
Guidelines for prevention of healthcare associated MRSA (HA-MRSA) currently
exist from the Center for Disease Control and Prevention, but there is limited evidence
about best practices implementation for MRSA prevention for pediatrics. The purpose of
this study was to conduct a systematic review in order to evaluate the current state of the
science with respect to MRSA interventions in order to reduce the transmission and
incidence of MRSA infections in pediatric inpatient settings in the United States. This
systematic review included literature found from 2005-2015 and specifically focused on
inpatient pediatrics. This study aimed to
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1. Identify interventions for the prevention of hospital-acquired MRSA in
pediatrics in the United States
2. Explore which prevention interventions appear to be most effective as defined
by decrease in transmission or incidence of infection
3. Develop informed suggestions to policy makers regarding current hospitalacquired MRSA prevention protocols for pediatrics
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CHAPTER II. LITERATURE REVIEW
Numerous strategies to reduce MRSA colonization and invasive infections have
been published, but very few of these have focused on pediatric patients. This is
problematic due to the fact that we cannot generalize results from adult studies to the
pediatric patients due to the fact that pediatric patients cannot take the same dosages, they
have weaker immune systems, and are often more susceptible to infections. The article
released in 2014 by Nelson et al., titled “One size does not fit all: why universal
decolonization strategies to prevent methicillin-resistant Staphylococcus aureus
colonization and infection in adult intensive care units may be inappropriate for neonatal
intensive care units” is important to note because it articulates why it is not necessarily
appropriate to apply strategies used with adult populations to pediatric populations. The
article discusses the recently published REDUCE MRSA TRIAL, a large multicenter,
randomized controlled trial that compared the efficacy of three surveillance and
decolonization strategies for reducing MRSA colonization and infection in adult ICUs
(Nelson et al., 2014). Some of the results of the trial that were intended for adult ICU
patients only has trickled down to the pediatric ICU patient population. Nelson (2014)
discussed that many prevention control procedures (such a Chlorohexidine) that have
been implemented in adult settings have not been studied in pediatric populations, or
worse are shown to have serious health implications (Nelson et al., 2014).
Because this systematic review is concerned with prevention and control
interventions of MRSA in the pediatric inpatient population, it is important to review
current policies of prevention or control of MRSA in this populations. Another important
aspect that warrants review is the prevalence and cost of MRSA infections in the
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pediatric inpatient population in order to assess the magnitude of the issues and lastly
review current prevention methods for this population. Because the REDUCE MRSA
TRIAL influenced protocols published by the AHRQ and CDC, it is important to next
review these protocols and discuss the gaps in the literature.
In this section, current guidelines and published protocols by the Center for
Disease Control and Prevention and the Department of Health and Human Services will
be discussed. More specifically, the Agency for Healthcare Research and Quality
(AHRQ) provides two guidelines that will be reviewed. Although all of these guidelines
make suggestions related to MRSA prevention/control among pediatric inpatients, none
of these guidelines are specific to this population and prevention of MRSA, providing
evidence that there is a gap in guidelines specifically intended for pediatric inpatients.
The first guideline from AHRQ titled “Diagnosis and management of complicated
intra-abdominal infection in adults and children: guidelines by the Surgical Infection
Society and the Infectious Disease Society of America” by Solomkin et al., (2010) is
important to discuss because MRSA is associated with surgical site infections (SSIs).
The guideline provides regimens for healthcare associated infections including MRSA
therapy. The author searched through both primary and secondary sources as well as
electronic databases in order to develop recommendations. The guidelines are based on
evidence from randomized clinical trials from 2002-2008, which used antimicrobials for
the treatment of intra-abdominal infection. A panel of experts in the infectious diseases,
surgery, pharmacology, and microbiology prepared these guidelines for the IDSA
(Infectious Disease Society of America).
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The guidelines suggest that those who are known to be colonized with MRSA or
are at risk of having an infection due to prior treatment failure and antibiotic exposure
should receive empiric antimicrobial coverage (Solomkin et al., 2010). Also,
Vancomycin is recommended for treatment of suspected or positive identified MRSA
infection for intra-abdominal infections. However, routine use of broad-spectrum agents
are not indicated for all pediatric inpatients with low suspicion or complication of
infection.
For pediatrics, the guidelines discuss that selection of specific antimicrobial
therapy with infection should be based on community vs. healthcare-associated infection
source, severity of illness, and the safety of antimicrobial agents in specific pediatric age
groups. For neonates, broad-spectrum antibiotics may be used with vancomycin being
the primary antibiotic used for MRSA control. However, the guideline also suggest that
therapy for pediatric patients with intra-abdominal infection is constrained by safety
concerns and that some forms of antibiotics such as tetracyclines and parenteral
fluorquinolones are not recommended when other alternatives exist. This shows that
there is no clarity of when broad-spectrum antibiotics use is appropriate when treating
neonates. In conclusion, the guideline did not mention prevention or control of MRSA in
pediatrics, and in fact it provides very limited information with respect to the treatment of
MRSA amongst pediatric patients.
The second guideline from AHRQ “Clinical practice guidelines by the Infectious
Diseases Society of America for the treatment of methicillin-resistant Staphylococcus
aureus infections in adults and children” (Liu et al., 2011) discusses key prevention and
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control guidelines for preventing, controlling, and treating of MRSA. This guideline
provides details about the management of MRSA in skin and soft-tissue infections
(SSTIs), the management of recurrent MRSA SSTIs, bacteremia, MRSA pneumonia,
MRSA bone and joint infections, and MRSA central nervous system infections. An
expert panel reviewed and synthesized the evidence published between 1961 and 2010.
Literature searches of PUBMED of the English-language literature were performed from
using terms “methicillin-resistant Staphylococcus aureus” or “MRSA”.
The results of this review suggest that, for pediatrics, almost all MRSA infections
are controlled and treated with Vancomycin; however, there is limited data about the
dosage efficacy, and safety of antibiotic usage. Consequently, the guideline suggests that
additional studies should be conducted. Current literature does suggest that in neonates
and young infants, topical treatments as an implementation of control methodology is
standard. The guideline recommends that for more-extensive diseases or in premature or
very-low birth weight, vancomycin or clindamycin should be used. For SSTIs, antibiotic
therapy is only recommended for the cohorts associated with extremes of age (ex.
pediatrics and elderly), but topical treatment is best approach.
The guidelines also have found that preventive educational messages on personal
hygiene and appropriate wound care are recommended for all patients with SSTIs. Also
environmental hygiene measures should be considered, with a focus cleaning efforts on
high-touch surfaces (i.e. surfaces that come into contact with people’s bare skin such as
door knobs, toilet seats). This recommendation is congruent with findings reported by
Giannini et al., (2009) which found that in a children’s cancer hospital, alcohol wipes on
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toilet seats prior to use resulted in a 50-fold reduction in mean daily bacterial counts and
eliminated MRSA, thus providing additional evidence that environmental
decontamination is key to avoiding spread of MRSA in pediatric patients. Lastly,
decolonization should be considered in selected cases based on severity of infection,
recurrence of MRSA despite implementing wound care and hygiene measures. In
conclusion, the guidelines published by Liu et al., (2011) did provide some information
on control and preventive measures, but in general the guidelines were more focused on
the adult inpatient population rather than on pediatric inpatient populations.
Another guideline that is important to discuss is the recent “Strategies to Prevent
Methicillin-Resistant Staphylococcus aureus Transmission and Infection in Acute Care
Hospitals: 2014 Update” by Calfee et al., (2014). The development of this guideline was
sponsored by the Society for Healthcare Epidemiology of America (SHEA) and was a
product of collaboration from the Infectious Disease Society of America, the American
Hospital Association, the Association for Professionals in Infection Control and
Epidemiology, and The Joint Commission. It is one of the most comprehensive
guidelines to date with respect to MRSA prevention and treatment in inpatient settings.
The guideline’s main purpose is to highlight practical recommendations for implementing
and prioritizing MRSA prevention efforts. The authors suggest that basic practices for
preventing MRSA transmission and infection are recommended for all acute care
hospitals and that active surveillance testing should be implemented when basic practices
are insufficient.
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Calfee and colleagues suggest that basic prevention practices include conducting a
MRSA risk assessment, educating healthcare personnel regarding MRSA, ensuring
compliance with hand hygiene recommendations, ensuring proper cleaning and
disinfection of equipment and environment, ensuring compliance with contact
precautions for MRSA-colonized and infected patients, and implementing a MRSA
monitoring program. If these steps are insufficient, compliance with basic practices
needs to be assessed. If compliance with basic practices is met and MRSA is not
effectively controlled, the guidelines suggest instituting one or more special approaches.
The list of special approaches include conducting active surveillance testing for MRSA
colonization among patients, implementing MRSA decolonization therapy, implementing
universal gowns and gloves, continuing to monitor MRSA rates, and continuing a MRSA
reporting and accountability system.
These are the general guidelines for prevention and control of MRSA among
acute inpatient facilities. However, the guidelines indicate that, in pediatric populations,
there needs to be more research on prevention protocols. For example, the guideline
reports that limited data are available on use of chlorohexidine for routine patient
cleansing for prevention of MRSA outside of the adult ICU setting (Rupp et al., 2012).
Also, when universal decolonization is suggested, the guidelines report that a few quasiexperimental single-center studies in the neonatal ICUs have shown a benefit of universal
decolonization with topical mupirocin in control of MRSA outbreaks and endemic
MRSA disease (Hitomi et al., 2000 and Delaney et al., 2013).
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The guidelines continue to report the fact that outside of neonates, universal
decolonization has not been studied in hospitalized children. Lastly, the guidelines report
that the neonatal ICU has a number of unique characteristics that should be considered
when an AST program is being implemented such as the size of the NICU, the number of
beds per pod, if any neonates such as twins share beds, etc. (Calfee et al., 2014). The
census after reading the guidelines from Calfee et al., (2014) suggest that there needs to
be more research conducted in the area of prevention and control of MRSA in pediatric
inpatients.
Echoing this information is the information published in the National Action Plan
to Prevent Health Care-Associated Infections: Road Map to Elimination published in
April of 2013. The National Action Plan is a product of the Federal Steering Committee
for the Prevention of Health Care-Associated Infections, which was established in 2008.
The steering committee’s members include clinicians, scientists, and public health leaders
form the Department of Defense, the Department of Health and Human Services, the U.S.
Department of Labor, and the U.S. Department of Veterans Affairs. The purpose of the
Steering Committee is to accelerate progress toward national infection reduction goals.
In the National Action Plan of 2013, the Steering Committee stated that in 2005,
there was an estimated 94,000 invasive MRSA infections in the U.S. which were
associated with nearly 18,000 deaths. Of these invasive infections, 86% were associated
with health care delivery (Kallen et al., 2010). Fortunately, rates of invasive health careassociated MRSA infections have decreased, but the optimal strategy for preventing and
controlling health care-associated MRSA has not been fully reached. In their discussion
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about the current gaps in knowledge and practice, the Steering Committee suggest the
need to understand the epidemiology of MRSA outside the adult ICU, especially in the
pediatric population. The committee also discussed the need to facilitate an understanding
of the role of various prevention strategies in reducing transmission of MRSA. Also an
important issue that is discussed is the need to translate accepted prevention practices to
areas outside the adult ICU, thus providing evidence that more research needs to be
conducted in order to adequately represent the pediatric population.
After review all current MRSA prevention and control guidelines, there is a
consensus that there needs to be more research conducted for prevention and control of
MRSA in pediatric inpatient settings. Now that we have a knowledge basis of current
guidelines, it is important to review the prevalence of MRSA in pediatric inpatient
settings in order to understand the magnitude of the problem.
The article by Kallen et al., (2010) surveyed 9 metropolitan areas covering a
population of approximately 15 million persons. Their main objective was to describe
changes in rate of invasive health care-associated MRSA infections from 2005-2008.
Kallen et al., (2010) found that there were 21,503 episodes of invasive MRSA infections,
17,508 were healthcare associated and that the rate of hospital-onset invasive MRSA
infections was 1.02 per 10,000 in 2005 and decreased 9.4% per year (95% confidence
interval [CI], 14.7% to 3.8%; P = .005). Although this shows vast improvement in our
healthcare settings, it is important to focus on data available for pediatric populations in
order to see if any improvements have been achieved there.
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Song et al., (2013) published an article that discusses the incidence of MRSA
infection in a children's hospital in the Washington metropolitan area from 2003 - 2010.
They found that in 2004 there were 0.93 per 1,000 patient-encounter MRSA infections,
then dramatically increased to 5.34 per 1,000 patient-encounter MRSA infections in 2007
and decreased to 3.77 per 1,000 patient-encounters by the end of 2010 (Song et al.,
2013). Another study conducted by Gerber et al., (2010) performed a retrospective,
observational study using the Pediatric Health Information System from more than 40 US
children’s hospitals. The study used discharge codes during the period of January 2002
to December 31st, 2007 and found that there was a significant increase in cases of MRSA
infection (from 6.7 cases per 1,000 admissions in 2002 to 21.1 cases per 1,000
admissions in 2007). This research shows that there is a need for prevention protocol
development at children’s hospitals across the nation. Next, we will focus more
specifically at the trends in incidence of MRSA in the NICU.
According to the National Nosocomial Infection Surveillance System, incidence
of late-onset MRSA infections in NICUs increased from 0.7 to 3.1 infection per 10,000
patient days from 1995-2004, showing an increase of 308% late-onset infections (Lessa
et al., 2009). This information is important because prevention methods will have to be
altered to specifically address late-onset MRSA infections. A better picture of the
colonization in neonatal and pediatric ICUs can be seen in the meta-analysis conducted in
2014 by Zervous et al. The meta-analysis identified 18 articles that were clinical studies
on MRSA colonization published from 2006-2013. The prevalence of colonization of
MRSA among NICU patient on admission was 1.5% (95% CI 0.9%-2.2%) compared to
the 3.0% (95% CI 1.9%-4.5%) among PICU patients. According to Zervous et al.,
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(2014), “the acquisition rate was 4.1% (95% CI 1.2%–8.6%) among the neonatal and
pediatric population, whereas among the neonatal population alone, 6.1% (95% CI 2.8%–
10.6%) of patients acquired MRSA during the NICU stay”. This supports all other
research discussed where steps need to be taken to prevent and control MRSA in the
vulnerable pediatric population. This population should be treated differently than the
adult population and should have specific protocols dedicated to pediatric inpatient
facilities. More research needs to be conducted in order to assess current incidence rates
and trends in MRSA pediatric inpatients as well as to deduce which prevention and
control policy has quantitatively shown a reduction in MRSA infection rates in pediatric
inpatients.
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Prevention of hospital-acquired methicillin-resistant staphylococcus aureus in U.S.
pediatric inpatients: a systematic review
R. See, V. Mahathre, A. Owen-Smith
…………………………………………………………………………………………………………………
ABSTRACT
Background: The vulnerability of the pediatric inpatient population in United States healthcare settings
establish a perfect environment for the acquisition and spread of methicillin-resistant Staphylococcus
aureus (MRSA). Although infection prevention and control protocols have well been established for
MRSA and for adult inpatients, there is a gap in literature in current guidelines on how to address MRSA
prevention and control in pediatric inpatients.
Objectives: To determine the effects of infection prevention and control strategies for preventing the
transmission of methicillin-resistant Staphylococcus aureus (MRSA) in United States pediatric inpatient
settings.
Search methods: In June-August 2015, we searched Campbell Collaboration Library, Cochrane Library,
PubMed, MEDLINE, Biological Abstracts, CINAHL Plus, and Web of Science for studies published
between January of 2005 and December 2015 by using relevant key terms for pediatric patients (ex,
children, infant, newborn, neonate) and prevention and control of MRSA.
Selection criteria: All primary data studies on infection prevention and control interventions for healthcare
associated MRSA in pediatric inpatient settings were eligible for inclusion.
Data collection and analysis: Two review authors independently reviewed the results of the searches.
Another review author was consulted for any discrepancies between categorization of articles. Data
extraction was conducted by one review author and was checked by a second review author.
Main results: 1,619 studies were initially identified, of which 21 studies met the criteria for inclusion. Of
the studies that met inclusion criteria, one was a randomized control trial, thirteen were retrospective cohort
studies, four were before and after studies, two were prospective cohort studies and one was a retrospective
case finding. Three studies (Song (2010), Robicsek (2009), and Gregory (2009)) found that Mupirocin or
antibiotic treatment did not eradicate MRSA colonization consistently and were unsuccessful in eliminating
continuing transmission of MRSA. However, the study by Delaney found that there was a significant
reduction in rates of S. aureus infection when comparing Mupirocin prophylactic period with the control
period. Another two studies (Constantini and Kjonegaard) found that screening was not identifying all of
the MRSA cases, and that HA-MRSA infection rates did not decline after implementation of ICU
screening, thus proving that this method was ineffective in regards to decreasing transmission and
incidence of MRSA infections.
Conclusion: There is a lack of research evaluating the effects on MRSA transmission of infection
prevention and control strategies in pediatric inpatient settings. More resources should be devoted to
understand the epidemiology of MRSA amongst the pediatric inpatient population as well as continued
research interventions to establish prevention and control protocols for this vulnerable population.
KEYWORDS Prevention, Control, MRSA, Neonates, Infant, Pediatrics, Children, Newborns, NICU,
PICU

M

RSA is an opportunistic grampositive bacteria that has in
recent years become a serious
healthcare as well as community threat.
In particular, MRSA is a common
bacterial infection amongst children,

especially in the NICU due to their
susceptibility to infections. Iwamoto et
al., (2013) found that although there is
an improvement due to the decrease in
the severity of and risk of mortality as a
result of infections, healthcare associated
	
  

	
  

MRSA infections were not significantly
reduced among pediatric populations
from 2005-2010. This indicates that
there needs to be further research as to
why there is an overall improvement
among adults but not for pediatric
inpatients. It is important to study
pediatric populations because according
to Milstone et al., (2011) 8.5% of
pediatric patients that were colonized
with MRSA on admission developed a
MRSA infection. Even more staggering
is the fact that 47% of patients who
became colonized with MRSA in the
pediatric ICU developed MRSA
infections (Milstone et al., 2011). In
comparison, Hudson et al; (2012) found
that the rates of MRSA carriage to be 612% in general hospital patients and 924% in ICUs. Various strategies for
prevention and eradication have been
used with various rates of success.
However, implementation of
standardized prevention methods has yet
to be developed specifically for
pediatrics, even though there is a clear
need for such protocols.
Guidelines for prevention of
healthcare associated MRSA (HAMRSA) currently exist from the Center
for Disease Control and Prevention, but
there is limited evidence about best
practices with respect to implementation
for MRSA prevention among pediatric
populations. The purpose of this study
was to conduct a systematic review in
order to evaluate the current state of the
science with respect to MRSA
interventions in pediatric inpatient
settings in the United States.
Specifically, this study aimed to:
1. Identify interventions for the
prevention of hospitalacquired MRSA in pediatrics
in the United States

2. Explore which prevention
interventions appear to be
most effective as defined by a
decrease in transmission or
incidence of MRSA
infections
3. Develop informed
suggestions to researchers
and policy makers in regards
to current hospital-acquired
MRSA prevention protocols
for pediatrics
METHODS
This systematic review included
literature found from 2005-2015 and
specifically focused on inpatient
pediatrics.
Search Strategy
With the help of the university
librarian, the first author conducted
scientific literature searches using the
Campbell Collaboration Library,
Cochrane Library, PubMed, MEDLINE,
Biological Abstracts, CINAHL Plus, and
Web of Science for studies published
between January of 2005 and December
2015 by using relevant key terms for
pediatric patients (ex, children, infant,
newborn, neonate) and prevention and
control of MRSA. All studies that were
not in the English language were
excluded for this systematic review.
From this original search, we identified a
total of 1,619 articles. After compiling
all sources and removing duplicate
articles we had a total of 698 original
articles.
Study Selection
Studies were required to meet the
following criteria in order to be included
in the review:
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1. Conducted in the United States
2. Evaluated the impact of an
intervention for prevention
and/or control of MRSA
3. Included children age 0-17 years
old
4. Implemented in an inpatient
setting

included in the article by Zara et al.,
(2000). Parameters included in the
assessment of study quality were based
on six categories of common problems
including descriptions, sampling,
measurement, analysis, results, and
other.
Data abstraction and synthesis

Studies that did not collect primary
data such as reviews, opinion articles,
and letters to editors were excluded.

By using standardized extraction
forms produced by Zara et al., (2000),
the first author independently extracted
all data. The third and first author
reviewed results of data abstraction form
in order to summarize for systematic
review. Discrepancies were discussed
and resolved by consensus.

The first round of review was
based on screening titles and abstracts
against the inclusion and exclusion
criteria. Two researchers who were
blinded by each other’s categorization
conducted this assessment. Then after
each researcher completed the first
assessment, categorizations were
compared and quality of categorization
was measured by percent agreed upon
(89%). The articles that were not
agreed upon were set aside and were
included in the full text review.

RESULTS
Description of Studies
We followed the Preferred
Reporting Items for Systematic Reviews
(PRISM) guidelines (Moher, Liberati,
Tetzlaff, Altman, & The PRISMA
Group, 2010) in order to conduct this
systematic review to best standards and
to report results systematically.
1,619 studies were originally
identified, of which 21 studies met the
criteria for inclusion. Of the studies that
met inclusion criteria, one was a
randomized control trial, thirteen were
retrospective cohort studies, four were
single-group pre-posttest studies, two
were prospective cohort studies and one
was a retrospective case finding. The
study identification and data abstracting
process is outlined in Figure 1.
Eleven out of twenty one studies
took place in the NICU, five were in a
children’s hospital, three were at the
entire hospital, and two were in hospital
systems. Most studies reported MRSA
colonization or infection as a percentage;

The second round of review was
based on reading the full article in order
to review any unclear abstracts. During
the second round of assessment, a third
researcher was brought in to settle any
discrepancies between those studies that
were not agreed upon for categorization
in the first round. Also any articles that
were met inclusion criteria were
reviewed again in the second round to
verify they fit criteria for inclusion.
After the second round of assessment, 21
articles met all criteria for inclusion.
Validity assessment
In order to assess the quality of
all included studies, the first author
completed the quality assessment form
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some studies reported patient-days at
risk while others reported attack rates.

identified successful increase in hand
hygiene compliance. The study by Song
et al; (2013) noted that sustaining hand
hygiene at 80% or higher was associated
with a 48% further reduction of MRSA
in comparison with the study by
Holzmann-Pazgal et al; (2011) that
found significant improvement in hand
hygiene compliance was not
independently associated with reduction
in MRSA transmission. This shows that
there is still some discrepancy in the
results as to the effectiveness of workerrelated outcomes in relation to decrease
in transmission and incidence of MRSA
infections.

Methodological quality of included
studies
Very few studies measured preintervention MRSA incidence. This is a
major flaw in the studies analyzed in the
fact that there is no comparison before
intervention to see if the intervention
plays a key role in MRSA transmission
reduction. Also, few studies actually
measured hospital worker-related
outcomes in order to see if healthcare
practitioners adhered to interventions.
Again, most studies did not assess preintervention hand hygiene compliance
rates, surveillance rates, or contact
precaution adherence rates. Another
important aspect of the studies included
that should be addressed is the fact that
none of the studies separated each
intervention piece. Every study included
multiple intervention types, so there is
no way of separating interventions in
order to see if individual intervention
components would be effective on its
own.
Only one study was a
randomized control trial, most were
observational studies, and in most of the
studies key details on the population
demographics were not described.
Through detailed team discussion we
were able identify key results and the
intervention types that we felt were most
important, thus allowing us to classify
studies based on intervention type and
summarize the results.
Hospital Worker-Related Outcome
Six studies identified healthcare
workers as being colonized with MRSA
and thus decolonized the healthcare
worker effectively. Three studies

Patient-Related Outcome
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Colonization rates varied
amongst all studies with Murillo (2009)
finding 9.3% of babies were colonized,
Song (2010) found 7% that were
colonized/infected, Khoury (2005) found
21.4% colonized, and Kaushik (2014)
found 57% were colonized at admission.
Three studies (Song (2010),
Robicsek (2009), and Gregory (2009))
found that Mupirocin or antibiotic
treatment did not eradicate MRSA
colonization consistently and were
unsuccessful in eliminating continuing
transmission of MRSA. However, the
study by Delaney found that there was a
significant reduction in rates of S. aureus
infection when comparing Mupirocin
prophylactic period with the control
period.
Another two studies (Constantini
and Kjonegaard) found that screening
was not identifying all of the MRSA
cases, and that HA-MRSA infection
rates did not decline after
implementation of ICU screening, thus
proving that this method was ineffective
in regards to decreasing transmission
and incidence of MRSA infections.

Limitations of review
Publication bias is always an
important bias to address in systematic
reviews. Publication bias is when
studies that have statistically significant
results are more likely to be published in
comparison to those whose results are
not statistically significant. Thus for the
purpose of this review, we must address
the fact that we were only able to collect
articles that were published in journals,
thus excluding all research that did not
make it to journal acceptance.
Another bias that that needs to be
addressed is the chance of
misclassification bias due to researcher
misclassifying articles by inclusion
criteria.
This study also has limitations in
the fact that it cannot be generalized to
outpatients or adult MRSA patients.
Implications for health policy, clinical
care, and future research
This systematic review has
shown that there is much research that is
still needed in order to find a solution to
reduce transmission of MRSA in
pediatric inpatient settings. The
implications that this systematic review
has are limited since the majority of the
studies included were observational and
tested multiple intervention components
simultaneously.
Given the heavy reliance on
Mupirocin as the topical antibiotic of
choice when treating MRSA, more
research needs to be conducted on the
efficacy of treatment among this
subpopulation. More research also
needs to be conducted to investigate
whether decolonization is effective and
cost-effective in preventing transmission
of MRSA amongst pediatric inpatients.

DISCUSSION
Strengths of review
This study has several strengths
including an extensive, thorough search
of current literature of which two
blinded reviewers categorized articles in
order to reduce misclassification bias.
Another strength found in this review is
that each article that met inclusion
criteria also went through a quality
assessment in order to rank articles by
best methods. Another strength of this
review is that the focus on the study
population is very precise, thus allowing
the results to be directly applied to
children in inpatient settings.
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The article by Kho on
implementing an email alert system in
hospital systems seems to be a very
effective approach that allows for
cohorting infected or colonized patients
immediately when they are admitted,
thus reducing transmission. More
research should be conducted to see if
this system is effective in high MRSA
incidence areas.
One suggestion for future
research would be to separate NICU
patients and pediatrics, as NICUs have
different practices (such as bed sharing
with twins) and are at higher risk due to
their compromised immune systems in
comparison to those pediatric inpatients.
CONCLUSION
This systematic review provides
some evidence that Mupirocin
decolonization is not effective in
reducing transmission of MRSA
amongst pediatric inpatients. Another
key report is that universal surveillance
may not be as effective as originally
thought, and thus mixed method
prevention interventions should be
instituted in order to have the best
patient outcome. However, much
research is needed on the pediatric
population in order to develop guidelines
in order to prevent transmission of
MRSA amongst pediatric inpatients.
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Kaushik et al;
(2014)
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(2009)
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(2005)

Children’s
Hospital
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Song et al;
(2010)

Gans et al;
(2013)

Setting
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   Professional
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tion/ Enforcement
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- BehavioralProfessional
- Legislation/Regula
tion/ Enforcement
- Clinical

- BehavioralProfessional
- Legislation/Regula
tion/ Enforcement
- Clinical

- BehavioralProfessional
- Legislation/Regula
tion/ Enforcement
- Clinical
- Public health/
medical
- Environmental

- BehavioralProfessional
- Legislation/Regula
tion/ Enforcement
- Clinical

Intervention Type

Table 1 Characteristics of included studies

RCS

BAS

PCS

RCS

RCS

Study
Design

- AS-N	
  
- D	
  

NA	
  

- 69% of initial uninfected patients developed
at least 1 MRSA infection
- At time of readmission, 144 (47.8%) of 301
patients who received any quantity of
Mupirocin were still colonized in contrast to
67 (63.2%) of 106 patients who did not
receive Mupirocin p=0.007
- High levels of Mupirocin resistance in a
MRSA isolate predicted continued
colonization. OR 4.1 [95% CI: 1.6, 10.7]

- 43% colonized during hospitalization
- 57% colonized at admission
- Cohorting colonized & infected infants
needed to prevent spread of infection

NA	
  
- AS-N	
  
- CP	
  
- C	
  

- 6 colonized (21.4%) out of 28 screened, 12
infected
- Original attack rate 5.3%
- Increased attack rate of 21.2%
- Transmission rate: 3.97 in 2001 vs. 0.46 in
2000 with relative risk= 8.59 [95% CI: 1.99,
37.00 p=0.0005]
- 42% developed 1 or more infections
- 3/87 patients developed SSI- 2 cases of
nonvancomycin sensitive Enterobacter and 1
Vancomycin-sensitive MRSA
- Application of local powder Vancomycin
during spine deformity correction had no
clinically significant effect on Creatinine
levels

- 6/110 (5.5%) HCW
colonized

AS-P	
  
CP	
  
E	
  
HH	
  
D	
  
En	
  

- 218 (7%) patients admitted to NICU
colonized/infected with MRSA
- Overall- 2.8 per 1,000 p-d-at-risk; 5.2 per
1,000 p-d-at-risk during outbreak
- 33.8% developed 1 or more infections
- Mupirocin decolonization was unsuccessful
in eliminating continuing transmission of
MRSA

Outcome Evaluation

NA

- Active screening
identified 67% infants
with MRSA
- Hand hygiene
compliance rate 65-80%
- Contact precaution
adherence 61-78%
- HCW screening- 3
colonized

AS-N
CP
E
HH
D
SCH
En
C

Process evaluation

- AS-P

-

-

Relevant
Outcomes
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System-17
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- Clinical

Public
health/medical care
system interventions

- BehavioralProfessional
- Legislation/Regula
tion/ Enforcement
- Clinical

Intervention Type

Table 1 Characteristics of included studies

RCS

RCS

RCS

PCS

BAS	
  

Study
Design

-

AS-N
CP
E
HH
D
C

- AS-N

AS-N
CP
HH
SCHW
En

- Other

-

Process evaluation

NA

NA

- 2/135 (1.5%) of HCW
screened identified as
being nasal MRSA
carriers, and 9 (6.7%)
colonized with MSSA

- June 2007-June 201012,748 email alerts on
6,270 unique patients
delivered

- AS-N	
   - Significant improvement in
- CP	
  
hand hygiene compliance
- HH	
  
p<0.001, not independently
associated with reduction
in MRSA transmission	
  

Relevant
Outcomes

-

-

-

-

-

-

-

-

-

-

Colonization detected in 138 (6.74%) infants
Of colonized detected 30/138 (21.74%) infected9/44 in 2004, 14/56 in 2005, 7/38 in 2006, overall
41 (2%)infected, 11/1,910 noncolonized infants
(0.58%) infected
119/1,616 (7.36%) inborn infants developed
MRSA colonization RR 1.67 [95:1.04, 2.69]
compared with 19/432 (4.4%) outborn infants
p=0.03
Annual incidence per 1,000 PD 0.915 in '04, 1.169
in '05, 0.893 in '06
Relative risk of MRSA for colonized patients is
37.75 (95:19.335,73.69) p<.001 compared to
noncolonized patients
Infection prevalence 0.997 (0.692-1.302),
colonization prevalence 3.356 (3.043, 4.205)
p<0.001, no difference in year

Of the 447 inborn and 167 outborn infants, 1.6%
and 3.6% were MRSA screen positive (p=0.0004,
fishers exact test)
Of inborn, none developed infection but among
outborn 50% had subsequent MRSA infection

Of 432 peripartum women, 40 (6.9%) and 10
(2.3%) were colonized with MSSA in the nares
and vagina, but no MRSA detected
MSSA isolated from nares of 14/399 (3.5%)
newborns and 1 MRSA (0.3%) case was identified

Only 10.9% (2595) of cohort age <18
1.9% cultured both MRSA and VRE
23% admissions of patients with previous history
of MRSA identified at different hospitals from
admitting hospital (range 19-30% of admissions
each year during 3 years

- Admission prevalence: 20/730 (2.7%) in 2006,
23/784 (2.9%) in 2007, 40/756 (5.3%) in 2008,
69/827 (8.3%) in 2009, significantly increased
between 06-08 p=0.01, between 07-08 p=0.02, ‘08‘09 p=0.02	
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- BehavioralProfessional
- Legislation/Regula
tion/ Enforcement
- Clinical

- BehavioralProfessional
- Legislation/Regula
tion/ Enforcement
- Clinical
- Public health/
medical

Intervention Type

BAS

RCS

Study
Design

Song et Children’s hospital - BehavioralRCS	
  
al; (2013)	
  303 beds
Professional
NICU LIII C
- Legislation/Regula
54 beds	
  
tion/ Enforcement
- Clinical

2 tertiary care
NICUs
LIIIB 50 bed
LIIIC 18 bed

NICU-LIV
47 beds

Murill
o et al;
(2009)

Chiu et
al;
(2011)

Setting

Study

Table 1 Characteristics of included studies

AS-N
CP
E
HH
D
SCHW
En

-

AS-N
CP
HH
En

- AS-P

-

Relevant
Outcomes

	
  

NA

-

-

-

HH compliance rate increased
from 50.3% pre to 84.0% post
intervention (relative risk [RR],
1.7; 95% [95%CI]: 1.6-1.9)
Compliance among physicians
& nurses increased from 48.6%
to 87.0% (RR, 1.4; 95% CI: 1.31.6) and from 46.5% to 77.9%
(RR, 1.3; 95% CI: 1.2-1.4),
respectively
Sustaining HH at 80% or higher
was associated with a 48%
further reduction of MRSA
acquisition (incident rate ratio,
0.52; 95% CI: 0.31 to 0.90) in a
unit that had comprehensive
MRSA prevention measures

- 6 of 175 health care workers (3.4%)
were also positive colonized

Process evaluation

-

-

-

-

-

-

-

-

-

Overall hand hygiene compliance rate and
MRSA acquisition rate in the unit was 81.0%
(n 1⁄4 501; N 1⁄4 627) and 1.7 per 1,000
patient-days, respectively
When hand hygiene compliance increased
from poor (<60%) to excellent (!90%), each
level of improvement was associated with a
24% reduction in risk of MRSA acquisition
(IRR, 0.76; 95% CI: 0.55-1.05)
When comparing hand hygiene compliance
rates above 80% with rates below 80%,
MRSA acquisition risk decreased significantly
by 48% (IRR, 0.52; 95% CI: 0.31-0.90)
Averaged 2.4 MRSA acquisitions/ month, the
48% reduction in acquisition risk represented
preventing 1.3 MRSA acquisitions each
month

(9.3%) 23/248 babies colonized
Jan-Dec 2005- infection rate of 2.14
infections per 100 admissions (0.99
infections per 1,000 patient-days)
Yearly MRSA infection rates in 2002, 2003,
and 2004 were 1.69, 1.35, and 1.16 per 100
admissions and 0.93, 0.58, and 0.56 per 1000
patient-days respectively
In 21 babies (91.3%) MRSA was eradicated
after 7 days of topical treatment but two
babies (8.7%) required an, additional 7 days
of treatment
There was a significant decrease in use of
Vancomycin with the number of Vancomycin
starts was reduced by 35% to 62% and the
number of infants treated with Vancomycin
per 1,000 patient days was reduced by 40% to
49% (P<0.05)
Implementation of guideline and sustainably
reduced Vancomycin use in NICUs with low
prevalence of MRSA infection
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NICU LIII
45 beds

Popoola et
al; (2014)

- BehavioralProfessional
- Legislation/Regula
tion/ Enforcement
- Clinical

NICU LIIIB - Behavioral60 beds
Professional
- Legislation/Regula
tion/ Enforcement
- Clinical

Delaney et
al; (2012)

- BehavioralProfessional
- Legislation/Regula
tion/ Enforcement
- Clinical

- Behavioralprofessional
- Legislation/Regula
tion/ Enforcement
- Environmental
- Clinical

Perinatal
ward in 571
bed tertiary
care
academic
setting

NICU LIII

Bertin et
al; (2006)

Intervention Type

Volk et al;
(2011)

Setting

Study

Table 1 Characteristics of included studies

RCS

RCS

RCS

RCF

Study
Design
AS-N
CP
E
HH
D
SCHW
En
C

-

-

AS-N
CP
E
HH
D
SCHW
C

AS-N
CP
HH
D
C

- AS-N

-

Relevant
Outcomes

- All HCW (204) screened -7
(3.4%) colonized
- All decolonized, 4 (80%)
recurrent colonization and again
decolonized

NA

NA

- Identification of strain to HCW
and cases, led to nasal Mupirocin
treatment to and work restrictions
for HCW, unsuccessfully treated
first time
- Retreated and successfully
decolonized with nasal Mupirocin
and 0.1% hydrocortisone butyrate
topical ear solution

Process evaluation

- 74/3,536 neonates (2.0%) culture grow
MRSA
- 19/74 (26%) had a MRSA infection, 11/66
(17%) colonized
- Mean quarterly incidence of NICU-onset
MRSA infection was 0.3 per 1,000 patient
days [95%: 0.0,0.8]
- MRSA transmission continued despite
increases in hand hygiene compliance
(p<0.001)

- Active screening identified 77 colonized
infants in 2008
- 2004- incidence 1.88 per 1,000 PDAR in preMupirocin time, rate decreased to 0.40 per
1,000pdar after implementation of intranasal
Mupirocin in august 2004; discontinued
Mupirocin 2005- incidence rate 1.42 per
1,000pdar, implemented infection control
and Mupirocin rate decreased to 0.33 per
1,000 PDAR
- Overall, when comparing Mupirocin
prophylactic period with control period,
significant reduction in rate of s. aureus
infection (p<0.0001) with a number needed
to treat of 49 and incidence rate ratio of 0.29
(95%: 0.166, 0.512)

- 4 (0.2%) of the 2,110 infants had nasal
MRSA colonization upon screening
- Strong association between maternal nasal
colonization and that of new infants
- Universal surveillance of maternal and
newborn may not be warranted

- Attack rate: 75% (9/12 neonates)
- In 2004, 6 colonized	
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Setting	
  

- Behavioral-Professional
- Legislation/Regulation/
Enforcement
Clinical	
  

Kjonegaar MICUd et al;
24 bed
(2013)	
  
SICU15 bed	
  

- AS-N
- AS-P
- CP

BAS	
  

	
  

- AS-N
- AS-P
-D

RCR	
  

	
  

- AS-N
- CP

- AS-N
- CP
-C

RCS	
  

RCS	
  

Relevant
Outcomes	
  

Study
Design	
  

NA	
  

NA	
  

NA	
  

NA	
  

Process
evaluation	
  

- HA-MRSA infection rates did not decline after implementation of ICU
screening
- The mean number of hospital admissions per month was 2,235 with a range
from 2,081 to 2,459. An average of 2.4 HA-MRSA infections per month was
identified (range, 0-7)

- The overall rate of colonization with MRSA and MSSA was 4.2% and
29.1%, respectively
- Screening of only the nose would have failed to detect 28.6% of the MRSA
cases
- Of the 102 patients, 85 had a groin swab (three positive) for MRSA, 9 had a
perianal swab (zero positive), & 8 had an umbilical swab (zero positive)
- Overall, 7 6.9%) of the 102 dually screened patients tested positive for
MRSA at least in one site

- 234/3934 (5.7%) pediatric patients colonized and 99 (2.4%) had cultureproven MRSA infection
- Colonization of infants less than a year old was 8.4% when compared to
those older than one at 5.2% (p=0.004)
- MRSA infection also more prevalent in children under 5 (3.6%) vs.
children older than 5 (1%) p=0.002
- Only 54% of those with MRSA infection had a positive nasal screen

	
  

87 (85.3%) of 102 colonized
15 (14.7%) of 102 invasive infection
7997 infants admitted to NICU-> 102 MRSA + (1.3%)
1.79 cases per 1,000 patient days [95%: 1.19, 2.49] in 20000 0.15 cases per
1,000 patient days [95%: 0.15, 0.44] in 2005 Poisson regression analysis
revealed a 31% decrease in incidence per year over this period p<0.0001
- However, sharp increase in first 8 months of 2007 with 1.26 cases per 1,000
patient days [95%: 1.03, 2.42]-> showing poison regression increase of
250% annual increase in incidence for this time
p<0. 0001
- Antibiotic treatment did not eradicate MRSA colonization consistently; 1/6
infants with BSI and 8/9 infants with SSTI remained colonized with MRSA
after treatment, did not decolonize other infants, only infected infants

-

Outcome Evaluation	
  

Retrospective Chart Review.
LII/III, Level II/III.
AS-N, Active Surveillance Nasal Cultures; AS-P, Active Surveillance swab other than nares; CP, Contact Precaution; E, Education; HH, Hand Hygiene; D, Decolonization;
SHCW, Screening Healthcare worker; En, Environment; C, Cohorting MRSA Patients.
PD, Patient-Days; PDAR, Patient Days At Risk	
  

RCS, Retrospective Cohort Study; RCF, Retrospective case finding; PCS, prospective cohort study; BAS, Before & After study; RCT, Randomized control trial,; RCR,

- Behavioral-Professional
- Legislation/Regulation/
Enforcement
- Clinical

Pediatric - Behavioral-Professional
center
- Legislation/Regulation/
123 beds	
  
Enforcement
- Clinical

- Behavioral-Professional
- Legislation/Regulation/
Enforcement
- Clinical

Intervention Type	
  

Costantini Pediatric
et al;
cardiac
(2013)	
  
surgery
patients

Thomson
et al;
(2011)	
  

	
  

Gregory et NICU
al; (2009)	
   LIIIB

Study	
  

Table 1 Characteristics of included studies	
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